

BC Society of **Laboratory Science** Presents



## BCSLS Telehealth Video Broadcast

With Dr. Bruce McManus

# “Molecular Biomarker Solutions for Better Health Care”

Thursday Jan 19, 2012

The goal of improving the specificity, overall efficacy, and efficiency of care for individuals at risk for or suffering from various diseases remains a driving force in the minds-eye of all clinical researchers and translators. Through work underway under the auspices of the Centre of Excellence for the Prevention of Organ Failure, a cross-disciplinary team of scientists and clinicians, working closely with patients, healthcare organizations, industry, and government, there is a commitment to providing better predictive, diagnostic, and prognostic management tools for physicians and their teams, and better markers of efficacy and toxicity for the pharmaceutical industry. These tools are molecular bio-signatures that can become cost-effective laboratory tests for the better care of patients throughout the life-cycle of heart, lung, or kidney failure, including in the setting of transplantation. In the remarks that will frame this topic, I will incorporate information about the nature and directions of personalized medicine, and how more sensitive and specific molecular markers may contribute in this exciting and chaotic era of health science and health care.



### **Bruce McManus, PhD, MD, FRSC, FCAHS, FACC, FCAP, FCCP, FRCPC**

Bruce McManus is Professor, Department of Pathology and Laboratory Medicine, at the University of British Columbia. He serves as Director, UBC James Hogg Research Centre at St. Paul's Hospital, Co-Director of the Institute for Heart + Lung Health, and Director of the NCE CECR Centre of Excellence for Prevention of Organ Failure (PROOF Centre). Dr. McManus served as the inaugural Scientific Director of the Institute of Circulatory and Respiratory Health, Canadian Institutes of Health Research, from December 2000 until April 2006. His basic and translational research program is focused on mechanisms, consequences, detection and prevention of injury and aberrant repair involved in inflammatory diseases of the heart and blood vessels, with particular emphasis on enteroviral infections of the heart and transplant vascular disease. He works in a cross-disciplinary setting on molecular biomarker discovery, development, commercialization and implementation in relation to heart, lung and kidney failure. Dr. McManus has co-authored ~350 peer-reviewed publications and 50 chapters, has edited four books, and holds several patents. He currently serves on editorial boards of several professional and scientific journals, and on many advisory committees and boards. He has long been committed to training and mentoring scientist trainees across a range of disciplines and at the interface of disciplines. He has convened many public and private sector partnerships in research. Dr. McManus has been recognized for his scientific contributions by numerous institutions and organizations through visiting professorships, lectureships, and awards. Among honours, he was co-recipient of the prestigious Max Planck Research Award in 1991. He was elected to the Royal Society of Canada as Fellow in the Academy of Sciences in 2002, and was elected as inaugural Fellow of the Canadian Academy of Health Sciences in 2005. Most recently, he delivered the 2011 Sarrazin Award Lecture to the Canadian Physiological Society.

**Details:** Thursday Jan 19, 2012 at 6:00pm – 8:00pm (PDT)

Registration fee for this event: \$28 BCSLS Members/\$56 Non-Members **Online Registration:** [www.bcsls/education](http://www.bcsls/education) - Live Events